Sugi Predict

Sugi Predict / Compounds / SCHEMBL1305145

SCHEMBL1305145

SCHEMBL1305145

CC(C)(C)c1ccc([P](=O)c2ccc(C(C)(C)C)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.48
▸ LMNA P02545 2/20 0.46
▸ TYR P14679 1/20 0.46
▸ ALDH1A1 P00352 5/20 0.43
▸ HDAC1 Q13547 1/20 0.41
▸ SRD5A2 P31213 1/20 0.40
▸ KIF11 P52732 2/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ MAPT P10636 3/20 0.38
▸ MAPK1 P28482 2/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ APEX1 P27695 1/20 0.37
▸ RECQL P46063 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2154715 0.91 L3MBTL1 (0.42) TSHRLMNATYRALDH1A1HDAC1
SCHEMBL28448347 0.89 POLB (0.52) TSHRLMNATYRALDH1A1CYP1A2
SCHEMBL1093877 0.78 TSHR (0.52) TSHRLMNATYRALDH1A1HDAC1
SCHEMBL424728 0.76 TSHR (0.73) TSHRLMNATYRALDH1A1HDAC1
SCHEMBL13454805 0.76 TSHR (0.50) TSHRLMNATYRALDH1A1HDAC1
SCHEMBL17703387 0.75 TSHR (0.39) TSHRLMNATYRALDH1A1HDAC1
SCHEMBL16154438 0.75 TSHR (0.39) TSHRLMNATYRALDH1A1HDAC1
SCHEMBL2886665 0.74 TSHR (0.48) TSHRLMNATYRALDH1A1HDAC1
SCHEMBL8384689 0.74 LMNA (0.52) TSHRLMNATYRALDH1A1HDAC1
SCHEMBL7526444 0.74 CES2 (0.46) TSHRALDH1A1SRD5A2KIF11CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119075972-A MoO reinforced by radio frequency plasma technology3/g-C3N4Catalyst and application of catalyst in phosphonation reaction 中国人民解放军军事科学院防化研究院 2024-12-06 — — CN claimed
CN-118908996-A A composition containing C (sp2) P bond or C (sp)3) Process for preparing organic phosphine compound of-P bond 烟台大学 2024-11-08 — — CN claimed
CN-115403623-B Method for preparing 2-pyrrolyl substituted phosphine oxide compound 湖南理工学院 2024-10-29 — — CN claimed
CN-114031639-B Preparation method of biphospide with P-O-C-P structure 烟台大学 2024-07-12 — — CN claimed
CN-114805430-B Preparation method of selenophosphide and thiophosphoride 烟台大学 2024-02-13 — — CN claimed
CN-113583042-B Preparation method of phosphoryl fluoride compound 烟台大学 2023-08-29 — — CN claimed
CN-111606945-B Preparation method of compound containing P-O bond or P-S bond 烟台大学 2023-06-20 — — CN claimed
CN-115403623-A Method for preparing 2-pyrrolyl substituted phosphine oxide compound 湖南理工学院 2022-11-29 — — CN claimed
CN-113583042-A Preparation method of phosphoryl fluoride compound 烟台大学 2021-11-02 — — CN claimed
CN-119075972-A MoO reinforced by radio frequency plasma technology3/g-C3N4Catalyst and application of catalyst in phosphonation reaction 中国人民解放军军事科学院防化研究院 2024-12-06 — — CN disclosed
CN-118908996-A A composition containing C (sp2) P bond or C (sp)3) Process for preparing organic phosphine compound of-P bond 烟台大学 2024-11-08 — — CN disclosed
CN-115403623-B Method for preparing 2-pyrrolyl substituted phosphine oxide compound 湖南理工学院 2024-10-29 — — CN disclosed
CN-114031639-B Preparation method of biphospide with P-O-C-P structure 烟台大学 2024-07-12 — — CN disclosed
CN-114805430-B Preparation method of selenophosphide and thiophosphoride 烟台大学 2024-02-13 — — CN disclosed
US-7208633-B2 Process for preparation of diphosphine compounds and intermediates for the process TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-04-24 — — US disclosed
US-20050027124-A1 Process for preparation of diphosphine compounds and intermediates for the process SPERA PHARMA, INC. (JP) 2005-02-03 — — US disclosed
EP-1452537-A1 PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS Takeda Chemical Industries, Ltd. (JP) 2004-09-01 — — EP disclosed
US-6730629-B2 HYDROGENATION CATALYST TAKASAGO INTERNATIONAL CORPORATION (JP) 2004-05-04 — — US disclosed
US-20030139285-A1 Novel asymmetric phosphine ligand TAKASAGO INTERNATIONAL CORPORATION (JP) 2003-07-24 — — US disclosed
EP-1318156-A1 Novel asymmetric phosphine ligand Takasago International Corporation (JP) 2003-06-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050027124-A1 Process for preparation of diphosphine compounds and intermediates for the process H1-10, ITPA, RER1 TSHR 1089/4885LMNA 2061/4885TYR 1367/4885
US-20030139285-A1 Novel asymmetric phosphine ligand PHOSPHO1, PAPSS1, PPM1F TSHR 2674/4885LMNA 4820/4885TYR 3410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.